Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 46708-175

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 46708-175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fesoterodine-figure1.jpg (Fesoterodine Figure1)

The text describes a figure labeled as "Figure 1" that shows a change in the number of micturitions (urinations) per 24 hours over the course of 12 weeks in a study. The figure displays results for a placebo group, a group taking Fosoterodine fumarate at a dose of 4mg, and a group taking Fesoterodine fumarate at a dose of 8mg. The text contains no further information about the study or its findings.*

FDA Label Image

Fesoterodine-figure2.jpg (Fesoterodine Figure2)

This text describes a figure that illustrates the change in urge incontinence episodes over a 12-week period in Study 1. The chart compares the results of a placebo group (consisting of 211 participants) with the results of two different drug treatments, Fosotorosine fumarate 4mg (N=198) and Fesolerodine fumarate 8mg (N=223). The figure shows the mean change from the baseline at weeks 2, 8, and 12.*

FDA Label Image

Fesoterodine-figure3.jpg (Fesoterodine Figure3)

This text presents the mean change from the baseline in terms of the number of micturitions per 24 hours in a study involving three groups: a placebo group with 266 participants, a group using fesoterodine fumarate 4mg with 267 participants, and a group using fesoterodine fumarate 8mg with 267 participants. The data is represented in Figure 3, which shows the change in the number of micturitions per 24 hours over time in weeks.*

FDA Label Image

Fesoterodine-figure4.jpg (Fesoterodine Figure4)

This is a figure depicting the change in urge incontinence episodes per 24 hours for three groups of participants (placebo, fesolorodine fumarate 4mg, and fesoterodine fumarate 8mg) over the course of several weeks. The graph shows that the two medication groups experienced a decrease in episodes compared to the placebo group. Mean change from baseline is not specified.*

FDA Label Image

30 Tablets (Fesoterodine mg 4)

This is a package of Fesoterodine, which is an extended-release tablet used to treat the symptoms of an overactive bladder such as urinary incontinence and urgency. The package contains 30 tablets and should be taken whole without chewing. The manufacturer is Vilacto Bio Inc. with an address in India. No dosage or prescription information is provided.*

FDA Label Image

30 Tablets (Fesoterodine mg 8)

FDA Label Image

Structure (Fesoterodine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.